STEM vs. ULBI, NVX, GWH, ELVA, CBAT, DFLI, FLUX, SES, TCX, and CAN
Should you be buying Stem stock or one of its competitors? The main competitors of Stem include Ultralife (ULBI), NOVONIX (NVX), ESS Tech (GWH), Electrovaya (ELVA), CBAK Energy Technology (CBAT), Dragonfly Energy (DFLI), Flux Power (FLUX), SES AI (SES), Tucows (TCX), and Canaan (CAN). These companies are all part of the "computer and technology" sector.
Ultralife (NASDAQ:ULBI) and Stem (NYSE:STEM) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
30.7% of Ultralife shares are held by institutional investors. Comparatively, 61.6% of Stem shares are held by institutional investors. 42.7% of Ultralife shares are held by company insiders. Comparatively, 10.2% of Stem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Ultralife has higher earnings, but lower revenue than Stem. Stem is trading at a lower price-to-earnings ratio than Ultralife, indicating that it is currently the more affordable of the two stocks.
Ultralife presently has a consensus price target of $13.00, indicating a potential upside of 15.56%. Stem has a consensus price target of $4.77, indicating a potential upside of 275.83%. Given Ultralife's higher possible upside, analysts plainly believe Stem is more favorable than Ultralife.
Ultralife has a net margin of 6.19% compared to Ultralife's net margin of -40.03%. Stem's return on equity of 10.31% beat Ultralife's return on equity.
Ultralife received 233 more outperform votes than Stem when rated by MarketBeat users. Likewise, 71.51% of users gave Ultralife an outperform vote while only 41.18% of users gave Stem an outperform vote.
In the previous week, Stem had 1 more articles in the media than Ultralife. MarketBeat recorded 2 mentions for Stem and 1 mentions for Ultralife. Stem's average media sentiment score of 1.95 beat Ultralife's score of 1.01 indicating that Ultralife is being referred to more favorably in the media.
Ultralife has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Stem has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.
Summary
Ultralife beats Stem on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding STEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
